Organon

Amarna Therapeutics announces appointment of Dr Henk Streefkerk as new CEO

Retrieved on: 
Wednesday, June 7, 2023

LEIDEN, Netherlands, June 7, 2023 /PRNewswire/ -- Amarna Therapeutics , a privately-held biotechnology company developing transformative gene therapies in a range of rare and prevalent diseases, including Hemophilia B, today announces the appointment of Dr Henk Streefkerk as the Company's new Chief Executive Officer and Medical Director.

Key Points: 
  • LEIDEN, Netherlands, June 7, 2023 /PRNewswire/ -- Amarna Therapeutics , a privately-held biotechnology company developing transformative gene therapies in a range of rare and prevalent diseases, including Hemophilia B, today announces the appointment of Dr Henk Streefkerk as the Company's new Chief Executive Officer and Medical Director.
  • Dr Streefkerk has a distinguished career as CMO of several biotechs, including PIQUR Therapeutics, Cellprotera and Rivia, and brings over a decade of experience working in big pharma including Novartis, Actelion and Organon.
  • "We are very pleased to introduce Henk Streefkerk as our new CEO.
  • Henk will be instrumental in leading Amarna towards the first in human clinical trial," said Thomas Eldered, Chairman of Amarna's supervisory board.

Amarna Therapeutics announces appointment of Dr Henk Streefkerk as new CEO

Retrieved on: 
Wednesday, June 7, 2023

LEIDEN, Netherlands, June 7, 2023 /PRNewswire/ -- Amarna Therapeutics , a privately-held biotechnology company developing transformative gene therapies in a range of rare and prevalent diseases, including Hemophilia B, today announces the appointment of Dr Henk Streefkerk as the Company's new Chief Executive Officer and Medical Director.

Key Points: 
  • LEIDEN, Netherlands, June 7, 2023 /PRNewswire/ -- Amarna Therapeutics , a privately-held biotechnology company developing transformative gene therapies in a range of rare and prevalent diseases, including Hemophilia B, today announces the appointment of Dr Henk Streefkerk as the Company's new Chief Executive Officer and Medical Director.
  • Dr Streefkerk has a distinguished career as CMO of several biotechs, including PIQUR Therapeutics, Cellprotera and Rivia, and brings over a decade of experience working in big pharma including Novartis, Actelion and Organon.
  • "We are very pleased to introduce Henk Streefkerk as our new CEO.
  • Henk will be instrumental in leading Amarna towards the first in human clinical trial," said Thomas Eldered, Chairman of Amarna's supervisory board.

CURE HOSTS "AI FOR GOOD" SUPER SESSION TO MAKE SENSE OF BIG DATA AND HIGH TECH AT 2023 BIO INTERNATIONAL CONVENTION ON JUNE 5

Retrieved on: 
Friday, June 2, 2023

NEW YORK, June 2, 2023 /PRNewswire/ -- Cure®, a healthcare innovation campus in New York City, today announced a one-of-a-kind Super Session featuring experts focused on leveraging AI for good as part of the company's presence at the Biotechnology International Convention, the largest global event for the biotech industry, in Boston, MA. from June 5 to 8, 2023.

Key Points: 
  • "The dizzying array of things AI can seemingly do – good, great, and worrisome – has the world of healthcare both excited and overwhelmed.
  • For the BIO Super Session, the panel Cure has gathered will discuss how we can optimally leverage AI and other advanced technologies while mitigating risks," said Cure Chief Executive Officer Seema Kumar.
  • The Cure booth also will host Cure Studios on the Road, capturing highlights and insights from leading biotech executives.
  • The booth will be open 8:00 am to 5:00 pm EDT in the BCEC Ground Level Halls A-C from June 5 to 8, 2023.

APEC CEO Summit USA 2023 To Convene World Leaders and Business Executives to Discuss Creating Economic Opportunity

Retrieved on: 
Saturday, May 27, 2023

SEATTLE, May 27, 2023 /PRNewswire-PRWeb/ -- The United States will host the Asia-Pacific Economic Cooperation (APEC) CEO Summit convening more than 1,000 business executives and welcoming key world leaders from across the Asia-Pacific at the Moscone Center in San Francisco from November 15-16, 2023.

Key Points: 
  • SEATTLE, May 27, 2023 /PRNewswire-PRWeb/ -- The United States will host the Asia-Pacific Economic Cooperation (APEC) CEO Summit convening more than 1,000 business executives and welcoming key world leaders from across the Asia-Pacific at the Moscone Center in San Francisco from November 15-16, 2023.
  • The APEC CEO Summit USA 2023 will feature 30+ speakers from the public and private sectors, representing various industries, emerging voices, entrepreneurs, philanthropists, and world leaders from large and small economies.
  • Visit the APEC CEO Summit USA 2023 website for the latest information on the program, newly confirmed speakers, and registration updates.
  • Members of the media are welcome to attend and cover the APEC CEO Summit USA 2023.

PM360 Announces Winners of The Ninth Annual ELITE 100 Awards

Retrieved on: 
Tuesday, May 16, 2023

NEW YORK, May 16, 2023 /PRNewswire/ -- PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device sectors, today announced the winners of its 9th Annual ELITE 100. The ELITE (Exceptional • Leaders • Innovators • Transformers • Entrepreneurs) represent the most influential people and teams in the healthcare and life sciences industries based on their career accomplishments. Out of more than 500 submissions, 100 winners are selected by the PM360 editorial staff across various categories that span every facet of the industry.

Key Points: 
  • NEW YORK, May 16, 2023 /PRNewswire/ -- PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device sectors, today announced the winners of its 9th Annual ELITE 100.
  • Out of more than 500 submissions, 100 winners are selected by the PM360 editorial staff across various categories that span every facet of the industry.
  • PM360 also selects one person as the "Uber ELITE," or the individual among the nominees who best personifies the criteria of a PM360 ELITE.
  • McCourt will serve as the keynote speaker at the annual ELITE 100 Awards Event to celebrate this year's winners.

Organon Reports Results for the First Quarter Ended March 31, 2023

Retrieved on: 
Thursday, May 4, 2023

Adjusted EBITDA margin was 33.7% in the first quarter of 2023 compared to 41.3% in the first quarter of 2022.

Key Points: 
  • Adjusted EBITDA margin was 33.7% in the first quarter of 2023 compared to 41.3% in the first quarter of 2022.
  • Net income for the first quarter of 2023 was $177 million, or $0.69 per diluted share, compared with $348 million, or $1.36 per diluted share, in the first quarter of 2022.
  • The dividend is payable on June 15, 2023, to stockholders of record at the close of business on May 15, 2023.
  • Total debt as of March 31, 2023 reflects a discretionary first quarter prepayment of $250 million on the company’s U.S. dollar-denominated term loan.

National Infertility Awareness Week® brings awareness activities across the country

Retrieved on: 
Monday, April 24, 2023

MCLEAN, Va., April 24, 2023 /PRNewswire-PRWeb/ -- RESOLVE: The National Infertility Association (RESOLVE) will recognize National Infertility Awareness Week®, April 23 through April 29, 2023. The movement brings together millions of Americans who want to remove the stigmas and barriers that stand in the way of building families. RESOLVE will rally the infertility community to raise awareness about the significant lack of access to family building options and emotional support for millions of women and men struggling to build a family. #FindYourVoice will be a message found on the official NIAW website and throughout RESOLVE's social media campaigns.

Key Points: 
  • RESOLVE: The National Infertility Association (RESOLVE) will recognize National Infertility Awareness Week®, April 23 through April 29, 2023.
  • The movement brings together millions of Americans who want to remove the stigmas and barriers that stand in the way of building families.
  • MCLEAN, Va., April 24, 2023 /PRNewswire-PRWeb/ -- RESOLVE: The National Infertility Association (RESOLVE) will recognize National Infertility Awareness Week® , April 23 through April 29, 2023.
  • The movement brings together millions of Americans who want to remove the stigmas and barriers that stand in the way of building families.

Organon To Report First Quarter and Host Conference Call on May 4, 2023

Retrieved on: 
Thursday, April 20, 2023

Organon (NYSE: OGN), a global women’s healthcare company will release its first quarter 2023 financial results on May 4, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.

Key Points: 
  • Organon (NYSE: OGN), a global women’s healthcare company will release its first quarter 2023 financial results on May 4, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.
  • Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/ .
  • A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website.
  • Institutional investors and analysts interested in participating in the call must register in advance by clicking on this link: https://conferencingportals.com/event/jgIqShwa .

Evolution Research Group, LLC Further Expands Early Phase Capabilities at Clinical Pharmacology of Miami (CPMI) with Increased Medical Team Expertise

Retrieved on: 
Wednesday, April 12, 2023

The expansion of the medical team has enabled CPMI to offer additional capabilities such as CSF sampling, which is currently in high demand.

Key Points: 
  • The expansion of the medical team has enabled CPMI to offer additional capabilities such as CSF sampling, which is currently in high demand.
  • Dr. Prezioso then accepted a role as Medical Director and Principal Investigator with a phase 1 unit in the northeast before relocating to Florida.
  • "I am thrilled to have joined the team at CPMI and am amazed by the growth they have experienced under the ownership of ERG.
  • Dr. Fernandez received his medical degree at the University of Miami, Miller School of Medicine, where he also did his residency training.

Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update

Retrieved on: 
Thursday, March 30, 2023

SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2022 and provided a company update.

Key Points: 
  • A proprietary, investigational cream formulation of sildenafil, the active ingredient in Viagra®, for topical administration to treat female sexual arousal disorder.
  • Financial Highlights for the Year ended December 31, 2022
    Cash and cash equivalents: $34.7 million at December 31, 2022, compared to $51.7 million at December 31, 2021.
  • Research and development expenses: $30.0 million in fiscal 2022 as compared to $30.6 in the prior year.
  • Daré will host a conference call and live webcast today at 4:30 p.m. Eastern Time to review financial results for the year ended December 31, 2022 and to provide a company update.